Acute hemorrhagic leukoencephalitis (AHLE) is a rare but fetal fulminant demyelinating disease of unknown etiology. It is commonly regarded as a severe variant of acute demyelinating encephalomyelitis (ADEM). Its rapid clinical deterioration and high mortality appeal to clinicians to attach importance to early diagnosis. Immunosuppressive therapy is the main management to attenuate the autoimmune process, but with varied response and prognosis.
- Membership
- Publications
- Resources
- Education
- Events
- Outreach
- Global Year
- Pain Management, Research and Education in Low- and Middle-Income Settings
- Sex and Gender Disparities in Pain
- Integrative Pain Care
- Translating Pain Knowledge to Practice
- Back Pain
- Prevention of Pain
- Pain in the Most Vulnerable
- Pain Education
- Joint Pain
- Pain After Surgery
- Global Year Campaign Archives
- My Letter to Pain
- IASP Statements
- ICD-11 Pain Classification
- Global Alliance of Partners for Pain Advocacy (GAPPA)
- National, Regional, and Global Pain Initiatives
- International Pain Summit
- Pain Awareness Month
- Global Year
- Careers
- About
- For Pain Patients and Professionals